<?xml version="1.0" ?>
<GlossaryTerm id="CDR0000046736">
  <TermName>di-dgA-RFB4</TermName>
  <TermDefinition>
    <DefinitionText>An anticancer drug that is a combination of a monoclonal antibody (RFB4) and an immunotoxin (dgA).</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </TermDefinition>
  <SpanishTermName>di-dgA-RFB4</SpanishTermName>
  <SpanishTermDefinition>
    <DefinitionText>Medicamento contra el cáncer que es una combinación de un anticuerpo monoclonal (RFB4) con una inmunotoxina (dgA).</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </SpanishTermDefinition>
  <DateLastModified>2005-03-02</DateLastModified>
</GlossaryTerm>
